Clinical Trials in Nashville

Showing 4041-4060 of 15,379 trials

Metabolic Effects of Angiotensin-(1-7)

NCT02646475

The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.

ObesityInsulin ResistanceHypertension+1 more

Vanderbilt University26 participantsStarted Feb 2016

Nashville, Tennessee, United States

Active Not RecruitingPhase 3< 1 mile

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.

Melanoma

Regeneron Pharmaceuticals1,564 participantsStarted Jan 2023

La Jolla, California, United States • San Francisco, California, United States • Santa Monica, California, United States +208 more locations

Metabolic Effects of Angiotensin-(1-7)

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Find Trials by Condition in Nashville

Pediatric ACL: Understanding Treatment Options

Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

Adalimumab in JIA-associated Uveitis Stopping Trial

A Study of SEA-CD40 Given With Other Drugs in Cancers

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Impairments That Affect Correct Inhaler Use in COPD

STEM-Parkinson's Disease

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Chronic Pain Management In Primary Care Using Behavioral Health Consultants

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions